Pfizer (PFE) Gets a Hold Rating from Barclays

By Austin Angelo

Barclays analyst Geoff Meacham maintained a Hold rating on Pfizer (NYSE: PFE) today and set a price target of $40. The company’s shares opened today at $43.68, close to its 52-week high of $44.46.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 6.2% and a 55.8% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, United Therapeutics, and Johnson & Johnson.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $47.

See today’s analyst top recommended stocks >>

The company has a one-year high of $44.46 and a one-year low of $33.20. Currently, Pfizer has an average volume of 19.46M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.